| 补肾益髓法治疗中间型珠蛋白合成障碍性贫血临床研究 |
| 投稿时间：2010-05-20 点此下载全文 |
| 引用本文：方素萍,张新华,吴志奎,王文娟,刘咏梅,李敏,王荣新,柴立民,张冲,陈玉英,吕鑫霞.补肾益髓法治疗中间型珠蛋白合成障碍性贫血临床研究[J].医学研究杂志,2010,39(10):41-44 |
| DOI：
|
| 摘要点击次数: 1676 |
| 全文下载次数: 1022 |
|
| 基金项目:国家重点基础研究发展计划资助项目；“973”计划资助项目（2010CB530406）；国家自然科学基金重大研究计划资助项目（90409003面上项目） |
|
| 中文摘要:目的探讨补肾益髓法从肾论治治疗两种不同类型（α-，β-型）中间型珠蛋白合成障碍性贫血的临床疗效。方法选取具有相同中医证候（肝肾阴虚，精血不足证），不同基因型的两种中间型地中海贫血患者（α-，β-型），用补肾益髓法的代表方益髓生血颗粒进行治疗，疗程3个月，采用自身对照方法，动态观察患者疗效性血液指标Hb、RBC、Ret、HbH的变化。结果益髓生血颗粒治疗中间型β-地中海贫血96例,有效78例，无效17例，有效率81.3%。有效病例患者的血液指标（Hb、RBC、Ret、HbF），自治疗第1个月起至3个月疗程结束均明显升高（均P<0.01）； 治疗中间型α-HbH病81例，有效62例，无效18例，有效率76.5%。 有效病例患者临床血液指标Hb、RBC、Ret，自第1个月起至3个月疗程结束均明显升高（P<0.01）。益髓生血颗粒治疗中间型地中海盆血总有效率为79.1%，β-地中海贫血和α-HbH病的疗效差异无统计学意义，服药后患者临床症状的明显改善与血液学指标的提高相一致。结论补肾益髓法治疗相同中医证候（肝肾阴虚精血不足证）不同基因型的（β-地中海贫血，α-HbH病）两种类型的中间型地中海贫血患者，均有明显疗效。 |
| 中文关键词:珠蛋白合成障碍性贫血 中间型（α-，β-型） 中医证候 补肾益髓法 益髓生血颗粒 |
| |
| Clinical Studies of Kidney Tonifying Therapy on Intermedia Thalassemia |
|
|
| Abstract:ObjectiveTo study the Traditional Chinese Medicine Theory “Kidney Engenders Marrow” by treating two genotypes intermedia thalassemia (both α- and β-) patients with kidney tonifying formula. MethodsSelf-cross-referred trials were used in treating two genotypes intermedia thalassemia patients (both α and β types diagnosed as Deficiency of Yin of both Liver and Kidney and asthenia of essence and blood in TCM methods) in higher frequency province of Guangxi with YiSuiShengXueGranule (YSSXG) for 3 months. The Hb, RBC, Ret and HbH level changes were detected dynamically every month. ResultsIn 96 cases of β-thalassemia patients treated with YSSXG, 78 cases were effective, 17 cases were ineffective, and the effective rate was 81.3%. The levels of blood indexes including Hb, RBC, Ret and HbF were significantly enhanced from the first month to the third month in those beta-thalassemia effective cases (P<0.01). And in 81 cases of α-thalassemia patients treated with YSSXG, 62 cases were effective, 18 cases were ineffective,and the effective rate was 76.5%. The levels of Hb, RBC and Ret were significantly enhanced from the first month to the third month in those beta-thalassemia effective cases (P<0.01). The total effective rate was 79.1%.No statistical difference was found between α- and β-thalassemia patients, and the significant improvement of clinical syndromes after treatment kept accordance with the enhancement of blood indexes. ConclusionNo matter what genotype intermedia thalassemia patients (both α and β types) with same TCM diagnose was, Tonifying kidney and myelinogenetic decoction YSSXG showed significant effects. |
| keywords:Thalassemia Intermedia (α- and β-) TCM diagnose Tonifying kidney and myelinogenetic decoction Yisuishengxue granule (YSSXG) |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
